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In recent weeks, two pioneering cardiac surgery teams, Dhital and colleagues in Australia (1) and
Large and colleagues in the UK (2), reported on what could rapidly become the best and sole
affordable solution to the relentlessly growing number of patients awaiting heart transplantation, i.e.,
transplantation of grafts obtained from donors after death following circulatory arrest, previously
termed “non-heart beating donors.” Both groups presented their slightly differing approaches to
organ procurement and evaluation at the 2015 Annual Meeting of The International Society
for Heart & Lung Transplantation, confirming several successful short-term outcomes for adult,
orthotopic heart transplantation with donation after circulatory death (DCD).
As would be expected, a handful of specialists from around the world enthusiastically recognize a
realistic complement to “traditional” cardiac donation after brain death (DBD), whereas others may
condemn this approach, considering the ethical, practical, and liability aspects as indomitable.Many
remain uncertain, possibly because of the apparent paradox, or at least the uncertainty, surrounding
transplantation of hearts obtained from donors after “cardiac death.” The Times recently titled
“«dead» hearts successfully transplanted into living patients” (2, 3). When it comes to DCD hearts,
it appears inappropriate to speak of donation after cardiac death, and potentially even misleading,
given that hearts are able to withstand limited periods of warm ischemia without cardioprotection.
Although in some countries determination of death based on cardiocirculatory criteria alone is
permitted, in many, a prolonged waiting period (e.g., 10–20min) between circulatory arrest and
organ procurement is required to ensure that permanent neurologic damage has occurred (4, 5). A
better terminology (6) would therefore be “DCD.”
One important aspect of these reports lies in the fact that this approach goes against the
established dogma that irreversible lesions immediately follow the onset of myocardial ischemia.
Indeed, the very first heart transplantations, including those performed by Barnard in 1967, were
performed with DCD organs (7). However, with the establishment of brain death criteria in
the 1970s, DCD hearts were considered “substandard” and therefore rapidly abandoned. More
recently, with revival of interest in DCD donation for improving graft availability notably for
kidney, liver, and lung, five categories of DCD patients have been established in the modified
Maastricht classification system (8). Distinctions between the different categories are based on
the specific circumstances surrounding donor death; for example, dead on arrival at the hospital
versus anticipated circulatory arrest following withdrawal of treatment. Furthermore, types of DCD
patients have also been classified as controlled or uncontrolled according to whether or not the
precise course of circulatory death is known. In theory, all DCD patients are potential heart
donors, provided that the inclusion criteria are met and ischemic time is limited; however, it is
currently unclear whether certain DCD categories would produce better outcomes. It could be
argued, for example, that Maastricht category III donors (anticipated circulatory arrest) would
be best suited for cardiac graft donation as conditions are controlled and pre-circulatory arrest
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interventions to limit heart damage may be possible. Yet these
donors may undergo asphyxiation, and are therefore expected
to experience pressure and volume overload both in the left
and right ventricles, possibly leading to cardiac damage (9).
This is in contrast to DCD donors who experience circulatory
arrest subsequent to exsanguination; in which no overload-related
damage, and thereby improved recovery, is expected (10); how-
ever, in this case circulatory arrest cannot be anticipated and
pre-ischemic cardioprotective interventions are impossible. In
addition to graft quality considerations, legal requirements may
influence the use of specific DCD donor categories for heart
transplantation.
Importantly, all potential DCD grafts undergo unavoidable
warm ischemia before cold preservation solutions can be instilled.
Notably, the warm ischemic times reported by Dhital for three
of their cases ranged between 22 and 28min, in agreement with
previous pediatric DCD heart transplantations (11) and multi-
ple pre-clinical studies demonstrating myocardial warm ischemic
tolerance of almost 30min. Therefore, a window of opportunity
remains to protect, harvest, and evaluate the heart. The real
challenge of DCD heart transplantation is thus to take advan-
tage of this limited opportunity to counteract risks related to
injury resulting from the inevitable ischemia and subsequent
reperfusion.
Now these recent reports of DCD heart transplantation are not
simply arbitrary provocations, but rather the result of mature,
albeit somewhat differing, strategies. Providing that the warm
ischemic time was <30min, Dhital and colleagues instilled
hearts with cardioplegic solution before establishment on an ex
vivo, portable perfusion apparatus primed with the donor’s own
(deleukocyted) blood. In all cases, hearts resumed contractile
activity and lactate metabolism was assessed for graft evalua-
tion before the decision to proceed with transplantation was
taken. Using a somewhat different approach, Large’s group in
the UK returned the heart to a beating state in situ to enable
functional graft evaluation prior to ex vivo perfusion. For DCD
hearts, graft evaluation is especially critical since no surgeon
would take the risk of transplanting a heart without assessing
its suitability. Indeed, as compared to traditional procedures in
which graft evaluation and the decision to transplant occur before
donor circulatory arrest, heart perfusion in DCD, whether it
be regional in situ or ex vivo perfusion, provides the oppor-
tunity for graft evaluation after donor circulatory arrest and
in a contracting mode. Also, with continuous perfusion on a
portable system, assessment can be prolonged, for example in
case of ambiguous results, and the decision to transplant can be
delayed.
All the same, precise, evidence-based protocols for every step of
the DCD heart transplantation process remain to be established.
Indeed, conventional methods used with DBD hearts may not
yield optimal outcomes asDCDhearts have undergone a period of
ischemia prior to procurement and may thus be less tolerant than
DBD hearts to additional exposure to damaging conditions. For
example, given that DCD hearts are already arrested at the time
of procurement and that strategies effective in limiting ischemic
heart damage may only be allowed at reperfusion (procurement)
for ethical reasons, conventional cardioplegic solutions may not
be optimal for DCD hearts. Indeed, Thatte and colleagues have
proposed a new cardioplegic solution developed specifically to
limit damage to DCD heart grafts (12). Along similar lines, DCD
may not be as tolerant to cold, static storage conditions as DBD
hearts, since some degree of ischemic damage has already been
initiated. Correspondingly, the two groups that recently reported
DCD heart transplantations both employed perfusion storage,
which, in addition to reducing ischemia during storage, also
permits the monitoring of graft function and metabolism, as
mentioned above.
Importantly, it may well be that evaluation reliability will be
improved with the addition of other parameters in the future.
We, and others, have shown that several relatively easily mea-
surable parameters correlate very well with post-transplantation
performance. For example, in pre-clinical ex vivo perfusion, Colah
and colleagues demonstrated that left ventricular hemodynamics
may be of potential value for graft evaluation (13); while our
group reported that not only hemodynamics, but also biochemical
parameters, such as oxygen consumption or markers of necro-
sis, provide information for the prediction of subsequent post-
transplantation contractile recovery (14, 15).
The DCD approach for cardiac transplantation should be con-
templated in light of not only new technological advances, such as
ex vivo graft perfusion which may contribute to a better recovery,
but also cardioprotective pharmacological and molecular strate-
gies. It is true that varying ethical and legal limitations, such
as the duration of the no-touch period, among countries are
likely to influence the precise clinical strategies chosen (8). Strate-
gies may involve the use of cardioplegic solutions and/or organ
perfusion, as well as other post-conditioning therapies, whether
biologic (cells, proteins, or genes), chemical (drugs), or physical
(hypothermia).
The recent reports from Australia and the UK may one day be
seen as critical events, marking fundamental changes in the way
we viewmedicine. By transplanting hearts with potentially higher
risks of post-operative dysfunction, both transplantation teamand
patient are asked to accept possibilities of higher post-operative
morbidity and mortality, as well as reduced survival as compared
to current standards. In other words, increasing the pool of donors
with DCD may imply a “weakening” of reported transplantation
results, although this “weakening” effect may already be ongoing,
considering the increasing use of marginal donors (16), or the
increasing donor age in Europe (17). On the other hand, this view
concentrates only on patients who receive heart transplants and, as
such, reflects performance of the heart transplantation procedure,
but not the overall situation of the real problem, i.e., the entire
group of transplantation candidates.
Obviously, many aspects must be thoroughly evaluated before
DCD heart transplantation can become a routine procedure.
Although these recent reports demonstrate the feasibility of this
approach as a concrete and rapidly applicable possibility for
helping more patients on the waiting list, it would be wrong to
generalize without careful ethical, cultural, legal, and practical
considerations. Nevertheless, there is an urgent need to find a
solution for the rapidly growing number of patients who will
never receive a DBDheart [in 2013, approximately 14.5 and 15.5%
cardiac transplantation candidates died in the US and Europe,
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respectively (18)].We definitely cannot continue to hope that large
donation campaigns or political interventions will substantially
influence organ availability. Also, we must accept that develop-
ment of alternative therapies, such as artificial hearts, drugs, stem
cells, or tissue engineering, remain long and cumbersome with no
guarantee of success. Conversely, the development of a DCDheart
transplantation program seems reasonable. Let us work together
to make it happen.
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